Kinase Inhibitor
Tepotinib for Lung Cancer
This trial will study the effects of tepotinib on lung cancer growth and spread, as well as safety, side effects, and quality of life. Pharmacogenetic research may also be conducted to study how genes impact the effectiveness of the drug.
Behavioral Intervention
Serious Gaming for Nausea and Vomiting
"This trial aims to see if a technology-based approach can help older adults with cancer better manage nausea and vomiting. Participants will be divided into two groups - one receiving the intervention and the other not. The
Targeted Therapy
SL-401 + Azacitidine/Venetoclax for AML and MDS
This trial is studying how well SL-401, azacitidine, and venetoclax work in treating patients with acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, or high-risk myelodysplastic syndrome.
Popular Filters
Trials for MPN Patients
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
INCB057643 +/- Ruxolitinib for Myelofibrosis
This trial is testing a new drug called INCB057643, alone or with ruxolitinib, for patients with certain blood cancers like myelofibrosis. The goal is to see if it can stop cancer growth or help other treatments work better. Ruxolitinib has been approved for the treatment of myelofibrosis and has shown clinical benefits in reducing symptoms and improving survival.
Bcl-2 Inhibitor
Navitoclax + Ruxolitinib for Myeloproliferative Disorders
This trial has 4 parts to evaluate the safety and how well the drug navitoclax works when given alone or with another drug, ruxolitinib. The trial will also look at how navitoclax affects QTc prolongation and how it affects the PK, safety, and tolerability of celecoxib in people with MPN or CMML.
Cancer Vaccine
Peptide-based Vaccine for Myeloproliferative Disorders
This trial is testing a new vaccine for patients with bone marrow disorders. Up to 10 patients will be enrolled over 12 months, with a maximum participation of 80 weeks. They will complete questionnaires and have bone marrow biopsies and standard of care lab tests.
Trials for Cancer Patients
CAR T-cell Therapy
Genetically Modified T-cell Therapy for Leukemia
This trial is testing the side effects and best dosage of genetically modified T-cells, which are a type of immune cell, in patients with leukemia or a certain type of cancer of the blood and bone marrow.
Alkylating agents
Chemotherapy + Bevacizumab for Abdominal Cancer
This trial is testing a new cancer treatment combining two drugs, one given directly into the abdomen and one taken by mouth. It is for people with a certain kind of cancer that has spread into the abdomen, and who have had surgery to remove as much of the cancer as possible.
Radiation Therapy
Radiation Therapy for Spinal Cancer
This trial compares 3 types of radiation therapy for cancer that has spread to the spine. EBRT and SBRT deliver radiation to the body from outside or target small areas respectively. Patients are randomly assigned to one of the 3 radiation therapies.
Trials With No Placebo
Virus Therapy
G207 + Radiation for Pediatric Brain Tumor
This trial tests a new treatment for children with aggressive brain tumors that haven't responded to other treatments. The treatment uses a special virus injected into the tumor, followed by a small dose of radiation. The virus kills cancer cells and helps the immune system fight the tumor.
View More Related Trials
Frequently Asked Questions
Introduction to appendix cancer
What are the top hospitals conducting appendix cancer research?
When it comes to clinical trials for appendix cancer, several top hospitals are leading the way in research and treatment. In Boston, the Dana Farber Cancer Institute is at the forefront with seven ongoing clinical trials dedicated specifically to this rare form of cancer. With a focus on appendix cancer, they are actively exploring innovative therapies and interventions. Meanwhile, in Tampa, Moffitt Cancer Center is making significant strides as well with six active trials focused on treating patients with this condition. Their commitment to advancing knowledge about appendix cancer brings hope to those affected by this disease.
Further down south in Houston, there are two noteworthy institutions making a difference in the field of appendix cancer research. The M D Anderson Cancer Center boasts five ongoing clinical trials aimed at improving outcomes for patients with appendix cancer. Similarly named but distinct from its counterpart, MD Anderson Cancer Center has also recorded remarkable progress since 2021 by initiating an important trial specific to appendix cancer; their dedication serves as a beacon of hope for future breakthroughs.
Finally, City of Hope located in Duarte contributes significantly to the fight against appendix cancer through their four active clinical trials that pursue new avenues of treatment and potentially life-saving interventions.
These hospitals' efforts not only bring attention and resources towards understanding and combating this uncommon form of malignancy but also offer solace to individuals battling it while bolstering prospects for improved treatments moving forward
Which are the best cities for appendix cancer clinical trials?
When it comes to appendix cancer clinical trials, several cities stand out as hubs of research and innovation. Boston, Massachusetts leads the way with 19 active trials investigating treatments like Venetoclax, Cardiac Lifestyle Program, and JSI-1187. New york, New York follows closely behind with 16 ongoing studies focused on promising options such as 5-Aminolevulinic acid Hydrochloride, ACE-536, and Ruxolitinib. Additionally, Houston, Texas and Duarte California each have notable contributions to appendix cancer research with 15 and 9 active trials respectively exploring various treatment avenues. Lastly, Saint Louis Missouri also plays a significant role in advancing knowledge through its participation in nine clinical trials targeting Tepotinib, faslodex 500mg ,and Intraperitoneal Oxaliplatin among others. These cities offer individuals diagnosed with appendix cancer access to cutting-edge clinical trials that may bring new hope for effective treatments and improved outcomes.
Which are the top treatments for appendix cancer being explored in clinical trials?
Clinical trials are shedding light on promising treatments for appendix cancer. Among the frontrunners is daratumumab, currently being investigated in six active trials dedicated to this specific type of cancer. Belantamab mafodotin follows closely behind with its involvement in four ongoing clinical trials. Additionally, lenalidomide shows potential as a treatment option, with three active trials exploring its efficacy against appendix cancer. These innovative therapies offer hope and new possibilities for patients battling this challenging disease.
What are the most recent clinical trials for appendix cancer?
Recent clinical trials offer promising possibilities for the treatment of appendix cancer. One notable study focuses on TGB-MF SubOpt R, with Part 1a investigating dose escalation in patients from Disease Group B. Another trial evaluates the efficacy of azacitidine as a potential therapeutic option for appendix cancer. Additionally, captopril is being explored in both Phase 1 and Phase 2 trials to determine its effectiveness against this type of cancer. The mEPIC trial aims to gain insights into new treatment strategies for appendix cancer through a Phase 2 study. Finally, Arm I investigates the combination of ASTX727 and venetoclax as a potential treatment approach in patients with appendix cancer. These ongoing trials provide hope for improved outcomes in individuals affected by this rare form of cancer.
What appendix cancer clinical trials were recently completed?
Recently completed clinical trials hold promise for advancements in the treatment of appendix cancer. In September 2017, the Ludwig Institute for Cancer Research concluded a trial evaluating ONCOS-102 as a potential therapy. Similarly, in July 2016, the University of Massachusetts, Worcester finished a trial focusing on Oxaliplatin. These significant milestones represent important steps toward improving outcomes for patients with appendix cancer and highlight ongoing efforts to uncover better treatment options through rigorous research and innovation.